AC Immune

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AC Immune and other ETFs, options, and stocks.

About ACIU

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

CEO

Andrea Pfeifer

CEOAndrea Pfeifer

Employees

161

Employees161

Headquarters

Lausanne, Vaud

HeadquartersLausanne, Vaud

Founded

2003

Founded2003

Employees

161

Employees161

ACIU Key Statistics

Market cap

319.97M

Market cap319.97M

Price-Earnings ratio

-7.85

Price-Earnings ratio-7.85

Dividend yield

—

Dividend yield—

Average volume

176.67K

Average volume176.67K

High today

$3.55

High today$3.55

Low today

$3.13

Low today$3.13

Open price

$3.55

Open price$3.55

Volume

234.16K

Volume234.16K

52 Week high

$5.14

52 Week high$5.14

52 Week low

$2.25

52 Week low$2.25

ACIU News

Seeking Alpha 1d

AC Immune stock jumps 20% on data for Parkinson's disease drug

AC Immune (NASDAQ:ACIU) stock shot up 20% Thursday after the company reported positive interim data from a Phase 2 study of its drug ACI-7104.056 in the treatme...

Benzinga 1d

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

AC Immune SA ACIU revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinso...

TipRanks 1d

AC Immune reports interim results from Phase 2 trial of ACI-7104.056

AC Immune (ACIU) announced positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti...